Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry
Hepatitis C virus (HepC) antenatal screening is now recommended in the US and is increasingly the standard of care globally. However, there are no current interventions to reduce perinatal HepC transmission. Virologic suppression via the use of direct-acting antiviral (DAA) medications during pregnancy may reduce risk of mother-to-child HepC transmission, but there is very limited data regarding the safety and efficacy profile of DAAs for mother-infant pairs and off-label use of DAAs is determined on a case-by-case basis.
The Treatment In Pregnancy for Hepatitis C: The TiP-HepC Registry project is an initiative of the Coalition for Global Hepatitis Elimination (CGHE) at the Taskforce for Global Health and supported by the Centers for Disease Control and Prevention.
The goal of the TiP-HepC project is to consolidate and leverage existing data and engage a community of practice among relevant stakeholders to prospectively inform appropriate decision-making for HepC treatment in pregnancy.
The objectives of the TiP-HepC project are to:
- Compile the existing knowledge, evidence, and initiatives related to HepC treatment in pregnancy. This includes sharing, aggregation, and analysis of existing data within HepC treatment programs globally demonstrating outcomes of mother-infant pairs exposed to DAA treatment during pregnancy or breastfeeding as a result of either intentional treatment or incidental exposures.
- Plan prospective data sharing through a multi-country safety and effectiveness registry for mother-infant pairs exposed to DAAs. No current standardized or unified registry exists to monitor mother-infant outcomes following exposure to DAAs.
- Build a community of practice and advocacy coalition dedicated to treatment for HepC in pregnant women. CGHE will develop an online knowledge hub and convene stakeholders using the knowledge generated through this project and profiling other efforts in the field.
Request for Collaboration
CGHE is seeking partners and collaborators for the TiP-HepC project to:
- Contribute existing data on outcomes of mothers and infants exposed to DAA medications in pregnancy
- Provide ideas, support, or case enrollment for a prospective registry to document outcomes of mothers and infants exposed to DAA medications in pregnancy
- Join a “Community of Practice” to learn about current evidence and efforts in the treatment of HepC for pregnancy women
To be involved, contact:
Dr. Neil Gupta, Coalition for Global Hepatitis Elimination, ngupta-consultant [at] taskforce.org